Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma
by
Ko, Je Yeong
, Han, Su-hyang
, Jung, Sungju
, Kim, Do Yeon
, Kim, Myung Sup
, Kang, Eunseo
, Yoo, Kyung Hyun
, Park, Jong Hoon
, Oh, Sumin
, Chun, Kyung-Hee
in
38/32
/ 38/47
/ 38/91
/ 631/67/1504/1610
/ 692/53/2422
/ Animals
/ Antisense RNA
/ Artificial intelligence
/ Biomedical and Life Sciences
/ Biomedicine
/ Cancer therapies
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Cell Line, Tumor
/ Cell Movement - genetics
/ Cell Proliferation
/ CpG Islands
/ DNA Methylation
/ Epigenetics
/ Gene expression
/ Gene Expression Regulation, Neoplastic
/ Hepatocellular carcinoma
/ Hepatocytes
/ Humans
/ Invasiveness
/ Liver cancer
/ Liver diseases
/ Liver Neoplasms - genetics
/ Liver Neoplasms - metabolism
/ Liver Neoplasms - pathology
/ Medical Biochemistry
/ Medical prognosis
/ Mice
/ Microvasculature
/ Molecular Medicine
/ Molecular modelling
/ N6-methyladenosine
/ Prognosis
/ Receptor, EphA3 - genetics
/ Receptor, EphA3 - metabolism
/ RNA, Antisense - genetics
/ RNA, Antisense - metabolism
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ Stem Cells
/ Tumor cell lines
/ Tumor microenvironment
/ Tumors
/ Vimentin
/ 생화학
2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma
by
Ko, Je Yeong
, Han, Su-hyang
, Jung, Sungju
, Kim, Do Yeon
, Kim, Myung Sup
, Kang, Eunseo
, Yoo, Kyung Hyun
, Park, Jong Hoon
, Oh, Sumin
, Chun, Kyung-Hee
in
38/32
/ 38/47
/ 38/91
/ 631/67/1504/1610
/ 692/53/2422
/ Animals
/ Antisense RNA
/ Artificial intelligence
/ Biomedical and Life Sciences
/ Biomedicine
/ Cancer therapies
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Cell Line, Tumor
/ Cell Movement - genetics
/ Cell Proliferation
/ CpG Islands
/ DNA Methylation
/ Epigenetics
/ Gene expression
/ Gene Expression Regulation, Neoplastic
/ Hepatocellular carcinoma
/ Hepatocytes
/ Humans
/ Invasiveness
/ Liver cancer
/ Liver diseases
/ Liver Neoplasms - genetics
/ Liver Neoplasms - metabolism
/ Liver Neoplasms - pathology
/ Medical Biochemistry
/ Medical prognosis
/ Mice
/ Microvasculature
/ Molecular Medicine
/ Molecular modelling
/ N6-methyladenosine
/ Prognosis
/ Receptor, EphA3 - genetics
/ Receptor, EphA3 - metabolism
/ RNA, Antisense - genetics
/ RNA, Antisense - metabolism
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ Stem Cells
/ Tumor cell lines
/ Tumor microenvironment
/ Tumors
/ Vimentin
/ 생화학
2024
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma
by
Ko, Je Yeong
, Han, Su-hyang
, Jung, Sungju
, Kim, Do Yeon
, Kim, Myung Sup
, Kang, Eunseo
, Yoo, Kyung Hyun
, Park, Jong Hoon
, Oh, Sumin
, Chun, Kyung-Hee
in
38/32
/ 38/47
/ 38/91
/ 631/67/1504/1610
/ 692/53/2422
/ Animals
/ Antisense RNA
/ Artificial intelligence
/ Biomedical and Life Sciences
/ Biomedicine
/ Cancer therapies
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Cell Line, Tumor
/ Cell Movement - genetics
/ Cell Proliferation
/ CpG Islands
/ DNA Methylation
/ Epigenetics
/ Gene expression
/ Gene Expression Regulation, Neoplastic
/ Hepatocellular carcinoma
/ Hepatocytes
/ Humans
/ Invasiveness
/ Liver cancer
/ Liver diseases
/ Liver Neoplasms - genetics
/ Liver Neoplasms - metabolism
/ Liver Neoplasms - pathology
/ Medical Biochemistry
/ Medical prognosis
/ Mice
/ Microvasculature
/ Molecular Medicine
/ Molecular modelling
/ N6-methyladenosine
/ Prognosis
/ Receptor, EphA3 - genetics
/ Receptor, EphA3 - metabolism
/ RNA, Antisense - genetics
/ RNA, Antisense - metabolism
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ Stem Cells
/ Tumor cell lines
/ Tumor microenvironment
/ Tumors
/ Vimentin
/ 생화학
2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma
Journal Article
VIM-AS1, which is regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma
2024
Request Book From Autostore
and Choose the Collection Method
Overview
Early tumor recurrence in hepatocellular carcinoma (HCC) remains a challenging area, as the mechanisms involved are not fully understood. While microvascular invasion is linked to early recurrence, established biomarkers for diagnosis and prognostication are lacking. In this study, our objective was to identify DNA methylation sites that can predict the outcomes of liver cancer patients and elucidate the molecular mechanisms driving HCC aggressiveness. Using DNA methylome data from HCC patient samples from the CGRC and TCGA databases, we pinpointed hypermethylated CpG sites in HCC. Our analysis revealed that cg02746869 acts as a crucial regulatory site for
VIM-AS1
(vimentin antisense RNA1), a 1.8 kb long noncoding RNA. RNA sequencing of HCC cells with manipulated
VIM-AS1
expression revealed
EPHA3
as a pathogenic target of
VIM-AS1
, which performs an oncogenic function in HCC. Hypermethylation-induced suppression of
VIM-AS1
significantly impacted HCC cell dynamics, particularly impairing motility and invasiveness. Mechanistically, reduced
VIM-AS1
expression stabilized
EPHA3
mRNA by enhancing the binding of IGF2BP1 to
EPHA3
mRNA, leading to increased expression of
EPHA3
mRNA and the promotion of HCC progression. In vivo experiments further confirmed that the
VIM-AS1‒EPHA3
axis controlled tumor growth and the tumor microenvironment in HCC. These findings suggest that the downregulation of
VIM-AS1
due to hypermethylation at cg02746869 increased
EPHA3
mRNA expression via a m6A-dependent mechanism to increase HCC aggressiveness.
Hypermethylation drives aggressiveness in liver cancer
Despite advancements in treatment, cancer remains a life-threatening disease that can recur (come back) and metastasize. Researchers found a knowledge gap in understanding how DNA methylation affects cancer progression. Researchers conducted an experiment to identify DNA methylation markers related to liver cancer prognosis. They used human liver cancer cell lines and analyzed DNA methylation and gene expression. The researchers discovered that hypermethylation of a specific DNA region in the
VIM-AS1
gene is linked to poor prognosis in liver cancer. They concluded that DNA methylation affects gene expression and cancer cell behavior. This finding could lead to new diagnostic and treatment strategies for liver cancer. Future research may explore how to target these epigenetic changes for better cancer therapies.
This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group,생화학분자생물학회
Subject
/ 38/47
/ 38/91
/ Animals
/ Biomedical and Life Sciences
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Liver Neoplasms - metabolism
/ Mice
/ Receptor, EphA3 - metabolism
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ RNA-Binding Proteins - genetics
/ RNA-Binding Proteins - metabolism
/ Tumors
/ Vimentin
/ 생화학
This website uses cookies to ensure you get the best experience on our website.